Development of comprehensive geriatric assessment-oriented treatment strategy for elderly cancer patients
Project/Area Number |
23501318
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Clinical oncology
|
Research Institution | Fukuoka University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
TAMURA Kazuo 福岡大学, 医学部, 教授 (60145422)
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | 高齢者 / がん薬物療法 / 包括的機能評価 / 日常生活の質 / 外来化学療法 / 機能評価 / 薬物動態 |
Outline of Final Research Achievements |
Older patients of same chronologic ages differ widely in physical and psychological function. Treatment strategy should be altered according to functional assessments of each patient. We underwent the comprehensive geriatric assessment (CGA), including psychological status, activities of daily living (ADL), instrumental ADL (IADL), nutritional status, comorbidity and cognitive function in patients with newly diagnosed malignant lymphoma. High ages, advanced stages and severe comorbidities were significantly associated with high incidence of treatment discontinuation, while high ages, ADL-dependencies and accumulation of severe comorbidities were significantly associated with low complete remission (CR) rates. ADL-dependency was significantly associated with overall survival. Performance status was not associated with either CR rate or OS. It indicates that CGA is an effective tool for predicting clinical outcomes in elderly patients who received anti-cancer chemotherapy.
|
Report
(5 results)
Research Products
(53 results)
-
[Journal Article] Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.2014
Author(s)
Ikari Y, Ogata K, Nakashima Y, Sato E, Masaki M, Katsuya H, Goto T, Tanaka T, Ishitsuka K, Takamatsu Y, Hara S, Tamura K.
-
Journal Title
Support Care Cancer
Volume: 22
Issue: 7
Pages: 1959-1964
DOI
Related Report
Peer Reviewed
-
[Journal Article] Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.2014
Author(s)
Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, Matsue K, Takamatsu Y, Usuki K, Tanimoto M, Ishida Y, Akiyama H, Onishi S.
-
Journal Title
Int J Hematol
Volume: 99
Issue: 2
Pages: 141-153
DOI
Related Report
Peer Reviewed
-
[Journal Article] Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.2014
Author(s)
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R.
-
Journal Title
J Clin Oncol
Volume: 32
Issue: 11
Pages: 1157-1163
DOI
Related Report
Peer Reviewed
-
[Journal Article] Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A).2014
Author(s)
Fukushima T, Nomura S, Shimoyama M, Shibata T, Imaizumi Y, Moriuchi Y, Tomoyose T, Uozumi K, Kobayashi Y, Fukushima N, Utsunomiya A, Tara M, Nosaka K, Hidaka M, Uike N, Yoshida S, Tamura K, Ishitsuka K, Kurosawa M, Nakata M, Fukuda H, Hotta T, Tobinai K, Tsukasaki K.
-
Journal Title
Br J Haematol
Volume: 166
Issue: 5
Pages: 739-748
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma2013
Author(s)
Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K
-
Journal Title
Intern Med
Volume: 52
Pages: 63-70
NAID
Related Report
Peer Reviewed
-
[Journal Article] Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL : results of a prospective study (ALL MRD2002 Study)2013
Author(s)
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. (16名, 6番目)
-
Journal Title
J Hematol Oncol
Volume: 6
Issue: 1
Pages: 14-14
DOI
Related Report
Peer Reviewed
-
[Journal Article] Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission2013
Author(s)
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M
-
Journal Title
Int J Hematol
Volume: 98
Issue: 2
Pages: 186-196
DOI
NAID
Related Report
Peer Reviewed
-
-
[Journal Article] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.2013
Author(s)
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K.
-
Journal Title
Int J Hematol
Volume: 98
Issue: 3
Pages: 337-345
DOI
Related Report
Peer Reviewed
-
[Journal Article] 多発性骨髄腫患者の末梢血幹細胞採取に対するbortezomibを含む導入療法の影響2013
Author(s)
牟田 毅, 宮本 敏浩, 藤﨑 智明, 大野 裕樹, 上村 智彦, 平安山 知子, 加藤 光次, 竹中 克斗, 岩崎 浩己, 衛藤 徹也, 高松 泰, 豊嶋 崇徳, 赤司 浩一
-
Journal Title
臨床血液
Volume: 54
Pages: 109-116
NAID
Related Report
Peer Reviewed
-
-
[Journal Article] Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission2012
Author(s)
Usuki K, Kurosawa S, Uchida N, Yakushiji K, Waki F, Matsuishi E, Kagawa K, Furukawa T, Maeda Y, Shimoyama M, Ago H, Yamano Y, Yano S, Fujishima N, Takamatsu Y, et al
-
Journal Title
Lymphoma Myeloma Leuk
Volume: 12
Issue: 6
Pages: 444-451
DOI
Related Report
Peer Reviewed
-
[Journal Article] Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial2012
Author(s)
Nishimura R, Rai Y, Matsuo F, Anan K, Hara S, Imamura S, Itoyanagi N, Kato M, Okido M, Kudaka M, Ishikawa E, Kamada Y, Watanabe R, Shirouzu M, Mitsuyama S, Takamatsu Y, Tamura K
-
Journal Title
Anticancer Res
Volume: 32
Pages: 3259-3265
Related Report
Peer Reviewed
-
-
[Journal Article] Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission2012
Author(s)
Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakamae H, Taguchi J, Sakura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, Fukuda T
-
Journal Title
Haematologica
Volume: 97
Issue: 6
Pages: 915-918
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review2011
Author(s)
Kamimura T, Miyamoto T, Nagafuji K, Numata A, Henzan H, Takase K, Ito Y, Ohno Y, Fujisaki T, Eto T, Takamatsu Y, Teshima T, Gondo H, Akashi K, Taniguchi S, Harada M
-
Journal Title
Bone Marrow Transplant
Volume: 46
Pages: 820-826
Related Report
Peer Reviewed
-
[Journal Article] Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia2011
Author(s)
Kunishima S, Kashiwagi H, Otsu M, Takayama N, Eto K, Onodera M, Miyajima Y, Takamatsu Y, Suzumiya J, Matsubara K, Tomiyama Y, Saito H
-
Journal Title
Blood
Volume: 117
Pages: 5479-5484
Related Report
Peer Reviewed
-
-
[Presentation] Predictive Significance of Serum Beta-2-Microglobulin levels and M-Protein.2014
Author(s)
Muta T, Iida S, Matsue K, Sunami K, Isoda J, Harada N, Saburi Y, Okamura S, Kumagae K, Watanabe J, Kuroda J, Aoki K, Ogawa R, Miyamoto T, Akashi K, Takamatsu Y.
Organizer
The 56th Annual Meeting of American Society of Hematology
Place of Presentation
サンフランシスコ, 米国
Year and Date
2014-12-07
Related Report
-
-
-
-
[Presentation] Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed myeloma2011
Author(s)
Takamatsu Y, Sunami K, Muta T, Tsukada J, Miyamoto T, Eto T, Higuchi M, Hata H, Hidaka M, Uozumi K, Otsuka E, Ogata M, Matsuoka H, Tamura K
Organizer
第73回日本血液学会総会
Place of Presentation
名古屋
Related Report
-
-
[Presentation] A phase I/II study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory myeloma2011
Author(s)
Takamatsu Y, Sunami K, Muta T, Tsukada J, Miyamoto T, Eto T, Higuchi M, Hata H, Hidaka M, Uozumi K, Otsuka E, Ogata M, Matsuoka H, Tamura K
Organizer
第36回日本骨髄腫研究会
Place of Presentation
東京
Related Report
-
-
-
-
-
[Presentation] 骨髄腫
Author(s)
高松泰
Organizer
日本臨床腫瘍学会第23回教育セミナー
Place of Presentation
横浜
Related Report
-
-
-
[Presentation] Bortezomib in combination with cytotoxic agent therapy for multiple myeloma
Author(s)
Takamatsu Y, Sunami K, Muta T, Tsukada J, Miyamoto T, Eto T, Higuchi M, Hata H, Hidaka M, Uozumi K, Otsuka E, Ogata M, MatsuokaH, Tamura
Organizer
第10回日本臨床腫瘍学会学術集会
Place of Presentation
大阪国際会議場
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-